Johnny Stilou’s strong financial background includes positions as CFO of Nuevolution AB (acquired by Amgen Inc.) and EVP & CFO of Veloxis Pharmaceuticals. Johnny has a successful track record of leading finance organizations in listed main market companies at Nasdaq as well as in-depth experience with capital markets and corporate finance.
Welcoming Johnny to Scandion Oncology, the Board of Directors and Bo Rode Hansen, President & CEO, would simultaneously like to thank our current CFO Carit Jacques Andersen for his commitment and great effort during the last four years.
Carit will soon be pursuing a career outside the company but will remain over the summer to ensure a smooth transition of the financial leadership.
“I am very pleased that we have attracted Johnny Stilou to Scandion Oncology. We are evolving the company and we need a focused capital market strategy in order to fund our operations optimally and secure a strong investor base. Johnny will bring a steady hand on the steering wheel with all the attributes required for a successful implementation of our capital market strategy,” said Bo Rode Hansen.
“At the same time, I would like to thank Carit Jacques Andersen for his valuable contributions to Scandion Oncology since 2017. Carit has been instrumental throughout the IPO process and in getting the company to where it is today”, he continued.
CV for Johnny Stilou
Age: 53, Danish nationality
2018 – 2021: CFO of Nuevolution (Acquired by Amgen Inc.)
2017 – 2018: CFO of Fritz Schur Technical Group
2007 – 2016: EVP & CFO of Veloxis Pharmaceuticals
2003 – 2006: CFO of Zensys
2001 – 2003: VP Corporate Finance at NetTest
1996 – 2001: VP Corporate Finance at GN
1989 – 1995: Senior Auditor at KPMG
Education: Cand Merc Aud – Master of Science (MSc) in Business Economics and Auditing. Executive Management Program, INSEAD.
For further information, please contact:
Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
The information was provided by the contact person above for publication, on June 2, 2021 at 8:30 a.m. CET.
About Scandion Oncology A/S
Scandion Oncology is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate drug, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities, including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the company's certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.